TY  - JOUR
AU  - Santoro, Cristina
AU  - Fuh, Beng
AU  - Le, Phu Quoc
AU  - Maes, Philip
AU  - Berrueco, Ruben
AU  - Mingot-Castellano, Eva Maria
AU  - von-Mackensen, Sylvia
AU  - Solms, Alexander
AU  - Wang, Michael
PY  - 2020
DO  - 10.1111/ejh.13420
UR  - http://hdl.handle.net/10668/15337
T2  - European journal of haematology
AB  - To report interim data from TAURUS, a study assessing real-world prophylactic treatment with unmodified, full-length recombinant FVIII BAY 81-8973 (Kovaltry® ; Bayer) indicated for haemophilia A. TAURUS (NCT02830477) is an international, open-label,...
LA  - en
PB  - John Wiley & Sons
KW  - Coagulation disorders
KW  - Haemophilia
KW  - Pharmacokinetics
KW  - Prophylaxis
KW  - Real-world evidence
KW  - Adolescent
KW  - Adult
KW  - Chemoprevention
KW  - Clinical Trials, Phase IV as Topic
KW  - Factor VIII
KW  - Hemophilia A
KW  - Hemorrhage
KW  - Humans
KW  - Male
KW  - Patient Reported Outcome Measures
KW  - Recombinant Proteins
KW  - Severity of Illness Index
KW  - Treatment Outcome
KW  - Young Adult
TI  - BAY 81-8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study.
TY  - research article
VL  - 105
ER  -